Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically proven Hodgkin's lymphoma Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER) Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria: EBV seropositive HIV negative HTLV-1 negative Hepatitis B surface antigen and hepatitis B core antibody IgM negative Hepatitis C antibody negative Must share at least 1 HLA haplotype with donor PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: Not specified Life expectancy: At least 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 2.5 times normal (unless liver metastases are present) If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required No hepatic dysfunction causing moribundity Renal: Creatinine clearance greater than 50 mL/min No renal dysfunction causing moribundity Cardiovascular: No cardiac dysfunction causing moribundity Pulmonary: No pulmonary dysfunction causing moribundity Other: No neurologic dysfunction causing moribundity No history of severe transfusion reactions with blood products (including fetal calf serum) Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics No concurrent antimetabolites Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified